4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Intermediate Ịdị ọcha>99.0% (HPLC)
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates nwere ịdị ọcha dị elu
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Aha Chemical | 4-Amino-3-Chlorophenol |
Ụdị okwu | 3-Chloro-4-Aminophenol;Lenvaint-G |
Nọmba CAS | 17609-80-2 |
Nọmba CAT | RF-PI1968 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C6H6ClNO |
Ibu molekụla | 143.57 |
Njupụta | 1.406±0.060 g/cm3 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Brown Solid ntụ ntụ |
1 H NMR Spectrum | Nkwekọrịta na Ọdịdị |
njirimara-HPLC | Oge njide yiri ọkọlọtọ |
Ụzọ ịdị ọcha / nyocha | > 99.0% (HPLC) |
Ebe Na-agbaze | 138.0 ~ 141.0 ℃ |
Ọnwụ na ihicha | <1.00% |
Ihe fọdụrụ na mgbanye | <0.30% |
Mgbakọta adịghị ọcha | <1.00% |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ndị etiti Lenvatinib Mesylate (CAS: 857890-39-2) |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
4-Amino-3-Chlorophenol (CAS: 17609-80-2) bụ ihe dị mkpa na-emepụta ọgwụ na-emepụta ọgwụ, nke a na-ejikarị eme ihe na nhazi na njikọ nke mgbochi tumor, ọrịa obi, ọrịa na-arịa ọrịa akwara.4-Amino-3-Chlorophenol bụ etiti dị mkpa na nkwadebe nke Lenvatinib Mesylate (CAS: 857890-39-2).Mepụtara Eisai Inc., lenvatinib mesylate bụ vaskụla endothelial growth factor receptor (VEGF) inhibitor nke nwere ọrụ megide VEGF subtypes 1, 2, na 3 ma kwadoro ya na FDA na 2015 maka ọgwụgwọ ọrịa cancer thyroid dị iche iche nke bụ na mpaghara. na-emegharị ugboro ugboro, metastatic, ma ọ bụ na-aga n'ihu ma ọ naghị anabata ọgwụgwọ iodine redioaktivu.Na Mee 2016, FDA kwadoro ọgwụ ahụ dị ka ọgwụgwọ ngwakọta na everolimus maka ọgwụgwọ nke carcinoma renal renal cell.N'ihi na VEGF (na fibroblast growth factor receptors, nke a maara dị ka FGFRs) na-eche na ha na-ekere òkè na ụzọ mgbaàmà nke obi, VEGF2R na mgbochi FGFR na-eche na ọ bụ usoro n'azụ isi mmetụta nke lenvatinib mesylate, nke bụ ọbara mgbali elu.